Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Electrical Impulse Device Improves Heart Failure Symptoms

By HospiMedica International staff writers
Posted on 08 Jan 2018
An innovative device delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart muscle, initiating multiple biochemical and neurohormonal changes in the myocardium.

The Impulse Dynamics (Stuttgart, Germany) Optimizer Smart implantable device is designed to deliver CCM signals during the absolute refractory period, just after the heart’s excitation. More...
As a result, the contractility of the myocardium increases, with no concomitant increase in oxygen consumption, enabling the heart to operate more efficiently. Therapy is based on an implantable pulse generator (IPG) unit that senses the heart’s electrical activity and delivers CCM signals via two electrodes placed in the right ventricle.

The IPG unit is recharged on a weekly basis using a home-based charger system, without supervision, which assures it has enough energy to provide therapy for years, minimizing the need for battery replacement. The charger has a built-in display that provides instructions and feedback to the patient about the charging process. A portable programmer allows medical personnel to customize and optimize signal parameters according to individual patient needs, with dynamic evaluations made using the patient’s electrocardiogram (ECG) and marker channels.

”CCM technology meets a major need globally, and we are committed to demonstrating the value of CCM therapy to healthcare systems worldwide to benefit more patients with heart failure,” said Simos Kedikoglou, MD, CEO of Impulse Dynamics.

“CCM therapy is a new therapeutic method used internationally to treat patients with chronic cardiac insufficiency,” said Professor Christian Wolpert, MD, of Ludwigsberg Clinic (Germany). “We have been applying this therapy to treat patients who have remained symptomatic despite a patient-specific medicinal regime at the Ludwigsburg Clinic for over four years now. Clinical studies have demonstrated that CCM positively enhances overall patient quality of life and physical exercise tolerance.”

CCM therapy is most suitable for patients with advanced heart failure (HF), a reduced ejection fraction (EF) higher than 20%, and normal QRS duration that cannot benefit from other device-based treatments, such as a cardiac resynchronization therapy (CRT) implantable device with pacemaker functionality.

Related Links:
Impulse Dynamics
Ludwigsberg Clinic


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Critical Care Conversion Kit
Adapter+
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.